Aligos Therapeutics, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 08/14/2024 | 7.26 M | $2.54 M | 5.27% | 4.65% |
| ECOR1 CAPITAL, LLC | 08/14/2024 | 6.39 M | $2.24 M | 0.00% | 4.09% |
| DEEP TRACK CAPITAL, LP | 08/14/2024 | 6.10 M | $2.14 M | 0.00% | 3.91% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 08/14/2024 | 5.00 M | $1.75 M | 102.88% | 3.20% |
| VIVO CAPITAL, LLC | 08/14/2024 | 3.55 M | $1.24 M | 0.00% | 2.27% |
| HHLR ADVISORS, LTD. | 08/14/2024 | 3.12 M | $1.09 M | 63.77% | 2.00% |
| BAKER BROS. ADVISORS LP | 08/14/2024 | 2.08 M | $726,740 | 0.00% | 1.33% |
| TANG CAPITAL MANAGEMENT LLC | 08/14/2024 | 1.65 M | $577,500 | 0.00% | 1.06% |
| VANGUARD GROUP INC | 08/13/2024 | 1.60 M | $558,376 | 57.48% | 1.02% |
| VERSANT VENTURE MANAGEMENT, LLC | 08/07/2024 | 1.46 M | $510,278 | -37.17% | 0.93% |
| OPALEYE MANAGEMENT INC. | 08/14/2024 | 1.26 M | $441,000 | -22.70% | 0.81% |
| UBS OCONNOR LLC | 08/14/2024 | 1.00 M | $350,000 | 100.00% | 0.64% |
| ACADIAN ASSET MANAGEMENT LLC | 08/06/2024 | 829,485 | $289,000 | 26.06% | 0.53% |
| BANK OF AMERICA CORP /DE/ | 08/14/2024 | 816,029 | $285,610 | -28.90% | 0.52% |
| RENAISSANCE TECHNOLOGIES LLC | 08/09/2024 | 768,839 | $269,094 | -4.88% | 0.49% |
| PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC | 08/13/2024 | 743,215 | $260,125 | 0.00% | 0.48% |
| NEWTYN MANAGEMENT, LLC | 08/14/2024 | 719,287 | $251,750 | -40.06% | 0.46% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 08/14/2024 | 655,515 | $229,430 | 0.00% | 0.42% |
| WOODLINE PARTNERS LP | 08/14/2024 | 531,204 | $185,921 | 100.00% | 0.34% |
| GEODE CAPITAL MANAGEMENT, LLC | 08/09/2024 | 405,694 | $142,022 | 8.75% | 0.26% |
| ALYESKA INVESTMENT GROUP, L.P. | 08/14/2024 | 284,233 | $99,482 | 100.00% | 0.18% |
| CITADEL ADVISORS LLC | 08/14/2024 | 277,363 | $97,077 | -2.91% | 0.18% |
| BLACKROCK INC. | 08/13/2024 | 227,406 | $79,592 | -25.14% | 0.15% |
| STATE STREET CORP | 08/14/2024 | 107,123 | $37,493 | 9.96% | 0.07% |
| NORTHERN TRUST CORP | 08/14/2024 | 91,950 | $32,183 | -0.07% | 0.06% |
| LMR PARTNERS LLP | 08/14/2024 | 50,000 | $17,500 | 100.00% | 0.03% |
| TOWER RESEARCH CAPITAL LLC (TRC) | 08/13/2024 | 46,476 | $16,267 | 479.36% | 0.03% |
| XTX TOPCO LTD | 08/12/2024 | 35,644 | $12,475 | -20.56% | 0.02% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 08/12/2024 | 31,383 | $10,984 | 0.00% | 0.02% |
| MILLENNIUM MANAGEMENT LLC | 08/14/2024 | 29,881 | $10,458 | -73.00% | 0.02% |
| CHOATE INVESTMENT ADVISORS | 08/08/2024 | 24,000 | $8,400 | 0.00% | 0.02% |
| PRUDENTIAL FINANCIAL INC | 08/13/2024 | 19,600 | $6,860 | 100.00% | 0.01% |
| HARBOURVEST PARTNERS LLC | 08/14/2024 | 18,783 | $6,574 | 0.00% | 0.01% |
| TWO SIGMA INVESTMENTS, LP | 08/14/2024 | 18,706 | $6,547 | 0.44% | 0.01% |
| CWM, LLC | 07/10/2024 | 16,891 | $6,000 | 0.00% | 0.01% |
| ZWJ INVESTMENT COUNSEL INC | 07/19/2024 | 14,500 | $5,075 | 0.00% | 0.01% |
| JANE STREET GROUP, LLC | 08/15/2024 | 13,666 | $4,783 | 100.00% | 0.01% |
| ZULLO INVESTMENT GROUP, INC. | 08/13/2024 | 13,000 | $4,550 | 0.00% | 0.01% |
| VIRTU FINANCIAL LLC | 08/09/2024 | 12,306 | $4,000 | 100.00% | 0.01% |
| CREATIVE PLANNING | 08/15/2024 | 10,050 | $3,518 | -35.27% | 0.01% |
| HIGHTOWER ADVISORS, LLC | 08/13/2024 | 10,000 | $4,000 | 100.00% | 0.01% |
| ADVISOR GROUP HOLDINGS, INC. | 08/13/2024 | 5,500 | $1,925 | 100.00% | 0.00% |
| MORGAN STANLEY | 10/17/2024 | 3,300 | $1,155 | 0.00% | 0.00% |
| CITADEL ADVISORS LLC | 08/14/2024 | 1,400 | $490 | -63.16% | 0.00% |
| JPMORGAN CHASE & CO | 12/26/2024 | 677 | $237 | 0.00% | 0.00% |
| UBS GROUP AG | 08/14/2024 | 362 | $127 | -96.66% | 0.00% |
| CITADEL ADVISORS LLC | 08/14/2024 | 300 | $105 | 50.00% | 0.00% |
| ZRC WEALTH MANAGEMENT, LLC | 07/09/2024 | 100 | $35,000 | 0.00% | 0.00% |
| WELLS FARGO & COMPANY/MN | 08/13/2024 | 0 | $0 | -100.00% | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 08/14/2024 | 0 | $0 | -100.00% | 0.00% |
Aligos Therapeutics, Inc.institutional Ownership - FAQ's
During the previous two years, 51 institutional investors and hedge funds held shares of Aligos Therapeutics, Inc.. The most heavily invested institutionals were:
XTX Topco Ltd: 0
MILLENNIUM MANAGEMENT LLC: 0
ZWJ INVESTMENT COUNSEL INC: 0
Versant Venture Management, LLC: 0
Pivotal bioVenture Partners Investment Advisor LLC: 0
Vivo Capital, LLC: 0
30.28% of Aligos Therapeutics, Inc. stock is owned by institutional investors.
Institutional investors have bought a total of 3.29 M shares in the last 24 months. This purchase volume represents approximately $135.13 M in transactions.